In a trial of the novel selective RET inhibitor selpercatinib that reported data from 19 patients with RET fusion-positive, previously treated thyroid cancer, objective responses were seen in 79% (Wirth et al. 2020). Here, RET is linked to thyroid gland carcinoma.